Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
200
resultados
Última actualización
17/04/2026 [06:54:00]
Resultados 75 a 100 de 200
Resumen de: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Resumen de: US20260097223A1
A system is provided for use with a subject suffering from cancer that includes one or more primary or metastatic solid tumors. The system includes nanoparticles including a magnetic metallic core and a phase-change material (PCM) that surrounds the magnetic metallic core and is configured to absorb latent heat of fusion by undergoing a phase change that occurs at a phase-change temperature of 42-80 degrees C. A radiofrequency (RF) transmitter is configured to transmit energy, in a pulse train alternating between high power and low power at a pulse frequency of 1 Hz-5 Hz, to at least a portion of the subject's body, such so that the nanoparticles are heated to the phase-change temperature of the PCM, and store energy from the pulse train in the PCM as latent heat of fusion. Other embodiments are also described.
Resumen de: WO2026075245A1
The present invention relates to: a modified mRNA comprising an open reading frame (ORF) encoding a protein, a poly A region on the 3'-side of the ORF, and biotin or an analog thereof bound to the 3'-end of the poly A region; and a pharmaceutical composition comprising the modified mRNA.
Resumen de: WO2026073350A1
A method for reprogramming native CD4+ T-cells is provided. The method comprises incubating the CD4+ T-cells with a Class 1 HDAC inhibitor for a period of time sufficient to increase cytotoxicity of the CD4+ T-cells in comparison to the cytotoxicity of native CD4+ T-cells. The method may be utilized to prepare cytotoxic tumor infiltrating CD4+ T-cells for use to treat cancer, including MHC-I deficient cancers.
Resumen de: WO2026074585A1
The present invention relates to a method for coating a medical device with nano- encapsulated drug using membrane technology. The said medical device is for interventional procedures. The invention discloses the design, formulation, technology features and potential clinical applications, emphasizing its role in improving outcomes in interventional procedures.
Resumen de: WO2026076250A1
The present disclosure relates to LNP formulations useful for uptake in the CNS or brain, for example, in some cases wherein the LNP is conjugated to an antigen binding fragment of an anti-transferrin receptor antibody. The present disclosure also relates to methods of delivering lipid nanoparticles (LNPs) systemically, for uptake in vivo in the central nervous system (CNS), such as to brain cells, and methods for assessment of the extent of uptake in CNS cells, such as brain cells. In some cases, methods allow for high throughput screening of multiple different LNPs in parallel.
Resumen de: WO2026074515A1
The present invention relates to nanoparticles formed by a hollow polymeric wall, capable of transporting drugs and active substances, or contrast media, across cellular membranes and releasing them at sites of interest. The nanoparticles are formed by self-assembly of poly(isobutene-alt-maleic anhydride) functionalised with an aminosaccharide.
Resumen de: US20260097001A1
0000 A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.
Resumen de: US20260097095A1
0000 PEGylated reconstituted high-density lipoprotein nanoparticles having the effect of preventing or treating neurodegenerative diseases are provided. Specifically, the present invention relates to nanoparticles and a method for producing the same, a phospholipid layer of the produced nanoparticles being protected by PEG due to PEG-lipid or a derivative thereof being included in the process of preparing a fluid comprising a hydrophobic material and a fluid comprising a hydrophilic material. The PEGylated nanoparticles have the ability to avoid the rejection mechanism of the immune response in the body while maintaining the existing transport ability across the blood-brain barrier, thereby having excellent stability and exhibiting long-term pharmacological effect due to high circulation ability in the body, and thus can be effectively utilized as a drug or a drug carrier.
Resumen de: AU2026202066A1
Abstract The present disclosure relates to lipid nanoparticles (LNP) and kits for making these, for the delivery of therapeutic molecules. Specifically, these LNPs comprise a plural of lipid components, comprising a lipid tail to be incorporated into a bilayer membrane, and a targeting moiety to provide selective delivery of the nanoparticle to a desired tissue. WO 2024/215614 PCT/US2024/023590 a §e « <0 ^iiis25 e$ *—£• s 5n sx s$?■' ’''NW.W.WA !i tft 4 . .'.W -t- ■MMMMMNM ! 5> 2«5K«K2 ijg fi, Jt* BSSSSSS.vvvvvvvvv.\j R~ SJSNWU wTttw Is »ja«^vvw^wvvv\vvw.v.v.v' **w»^^Vi>>>>>>>>mV»\ »yv 8?/* «w<5t\\\\\\v-: C5:::: , ...WKTOCWCWSSK5 S < > 5$8 'w*XNN'\'\'\'vXJ •-v--------w.v.vvr ^ y Jj» JAWXWAAft- I«S35 .VO.Vv\v!!vv!vv vWJJK s sssSt!
Resumen de: US20260097112A1
0000 The present disclosure provides vaccine compositions comprising a plurality of distinct antigens. Also provided are nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of distinct antigens. The plurality of distinct antigens comprises a combination of influenza antigens. The vaccine composition can be formulated for delivery as a mRNA/LNP, a recombinant protein, a virus-like particle (VLP), or DNA. Methods of preventing an influenza infection and methods of inducing an immune response are also disclosed.
Resumen de: US20260098070A1
0000 Provided herein are fusion molecules comprising a SMAGP extracellular domain that can modulate leukocyte activity. Also provided are polynucleotides, vectors, and host cells encoding these fusion molecules, and methods of making and using these fusion molecules.
Resumen de: US20260096998A1
0000 The present disclosure provides complexes and methods of use. In some embodiments, a complex described herein is a complex comprising a cationic polymer, an anionic polymer, and a monomeric RNA molecule, wherein the cationic polymer and the monomeric RNA molecule form a core complex encapsulated by the anionic polymer. In some embodiments, a complex comprises a linear cationic polymer, an anionic polymer, and a monomeric RNA molecule, wherein the cationic polymer and the monomeric RNA molecule form a core complex encapsulated by the anionic polymer.
Resumen de: US20260097103A1
0000 The present invention relates to a composition comprising a solid carrier, an enzyme or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the enzyme or the fragment thereof by embedding the enzyme or the fragment thereof, and a functional constituent immobilized on the surface of the protective layer. The present invention also relates to a method for the prevention, delay of progression or treatment of lung cancer in a subject using said composition and methods of producing said composition.
Resumen de: US20260097138A1
Metal based nanoparticles coated with a polymer functionalized with thiol groups and —NH groups are provided. The polymer can be thiolated chitosan, thiolated and aminated alginic acid, thiolated and aminated hyaluronic acid, or a protein such as albumin or gelatin, or a synthetic thiolated and aminated polymer such as α-thio-ω-amino polyethylene glycols. The groups are linked to a ligand of the integrin family receptors via a heterobifunctional crosslinker bearing functional groups able to bind to amino groups such as N-hydroxysuccinimidyl ester group (NHS ester), an isocyanate group (—NCO), an isothiocyanate group (—NCS), a Sulfo-N-hydroxysuccinimidyl ester group (sulfo-NHS ester), or a carboxylic acid group which is connected by activation with carbodiimide coupling agents; and/or a functional group able to bind thiol groups.
Resumen de: US20260097000A1
The present invention relates to a method of treatment wherein a composition comprising a cannabinoid and an amphiphilic carbohydrate compound such as GCPQ is administered intranasally. The method of treatment is particularly suitable for use in central nervous system disorders. The invention further relates to the composition when formulated with other components in pharmaceutical compositions for use in therapy.
Resumen de: US20260096990A1
0000 A polymeric delivery system delivers a biologic to cells. In some embodiments, the polymeric delivery system includes polyplexes. Each polyplex includes at least one charged polymer and at least one biologic. The at least one charged polymer includes a polyester copolymer of a polyol and a polycarboxylic acid modified with at least one charged moiety having an opposite charge from a net charge of the at least one biologic. In other embodiments, the polymeric delivery system includes self-assembled particles including a block copolymer and a biologic associated with the block copolymer. The block copolymer includes a first block of a polyester copolymer of a polyol and a polycarboxylic acid and a second block of a second monomer or a second polymer.
Resumen de: US20260096988A1
0000 The present application provides liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides. The present application also provides nanodiamond complexes and particles as carriers for anti-cancer agents
Resumen de: US20260096997A1
0000 A composition for the controlled release of a nucleic acid such as short interfering RNA or messenger RNA, comprising silicon nanoparticles, at least one amino acid, and at least one lipid, wherein the silicon nanoparticles comprise at least 50% by weight silicon. Also related compositions and methods.
Resumen de: AU2026202230A1
Nucleic acid constructs that allow insertion and/or expression of a sequence of interest, such as a transgene, are provided. Compositions and methods of using such constructs for expression of a polypeptide or therapeutic agent, for example, are also provided. ar a r
Resumen de: AU2026202084A1
AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) 5 vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor 10 receptor operably linked to a signal peptide. ar - a r
Resumen de: US20260096986A1
Drug delivery systems comprising a floating interpenetrating network (IPN) are provided. The pharmaceutical compositions contain at least one IPN forming system, at least one drug, and at least one gas generating agent, such that upon oral ingestion of the compositions, a floating IPN is formed in situ. These floating IPN provide extended release of the drug entrapped therein for at least about 3 hours.
Resumen de: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Resumen de: EP4721759A1
0001 A lipid nanoparticle (LNP) composition for delivering a nucleic acid drug, and a preparation method therefor and a use thereof. The composition prepared by mixing a steroid-cationic lipid compound with a helper lipid and a polyethylene glycol modified phospholipid has better stability and transfection efficiency. The use of an LNP to deliver a nucleic acid, such as mRNA, can efficiently and stably deliver a nucleic acid drug to a target cell or organ, and meanwhile, the LNP can be used for aerosol inhalation administration of the mRNA and can also be used for developing a lyophilized preparation of the mRNA. A higher specific antibody response can be induced in an experimental animal, and the compound has better safety.
Nº publicación: EP4719414A2 08/04/2026
Solicitante:
UNIV NEBRASKA [US]
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
BOPI
Sede Electrónica
